RS50200B - Kalijumova so (s) - omeprazola - Google Patents

Kalijumova so (s) - omeprazola

Info

Publication number
RS50200B
RS50200B YU53801A YUP53801A RS50200B RS 50200 B RS50200 B RS 50200B YU 53801 A YU53801 A YU 53801A YU P53801 A YUP53801 A YU P53801A RS 50200 B RS50200 B RS 50200B
Authority
RS
Serbia
Prior art keywords
omeprazole
potassium salt
hydrate
crystalline
gives
Prior art date
Application number
YU53801A
Other languages
English (en)
Inventor
Maths Nilsson
Original Assignee
Astrazeneca Ab.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab., filed Critical Astrazeneca Ab.,
Publication of YU53801A publication Critical patent/YU53801A/sh
Publication of RS50200B publication Critical patent/RS50200B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kalijumova so (S)-omeprazola oblika B, naznačena time, što je u obliku hidrata, kristalna i daje difraktograme X-zraka na prahu koji pokazuju suštinski sledeće d-vrednosti. Prijava sadrži još šest patentnih zahteva
YU53801A 1999-01-28 2000-01-18 Kalijumova so (s) - omeprazola RS50200B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound

Publications (2)

Publication Number Publication Date
YU53801A YU53801A (sh) 2004-07-15
RS50200B true RS50200B (sr) 2009-07-15

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
YU53801A RS50200B (sr) 1999-01-28 2000-01-18 Kalijumova so (s) - omeprazola

Country Status (40)

Country Link
US (1) US6511996B1 (sr)
EP (1) EP1149090B1 (sr)
JP (1) JP2002535401A (sr)
KR (1) KR100624054B1 (sr)
CN (1) CN1231477C (sr)
AR (1) AR022425A1 (sr)
AT (1) ATE236899T1 (sr)
AU (1) AU768676B2 (sr)
BG (1) BG65060B1 (sr)
BR (1) BR0007647A (sr)
CA (1) CA2357744C (sr)
CZ (1) CZ300504B6 (sr)
DE (1) DE60002042T2 (sr)
DK (1) DK1149090T3 (sr)
DZ (1) DZ3001A1 (sr)
EE (1) EE04240B1 (sr)
EG (1) EG23980A (sr)
ES (1) ES2193937T3 (sr)
HK (1) HK1041259B (sr)
HU (1) HU226766B1 (sr)
ID (1) ID30095A (sr)
IL (1) IL144107A0 (sr)
IS (1) IS2019B (sr)
MY (1) MY119095A (sr)
NO (1) NO319719B1 (sr)
NZ (1) NZ512804A (sr)
PL (1) PL197881B1 (sr)
PT (1) PT1149090E (sr)
RS (1) RS50200B (sr)
RU (1) RU2237666C2 (sr)
SA (1) SA00200895B1 (sr)
SE (1) SE9900274D0 (sr)
SI (1) SI1149090T1 (sr)
SK (1) SK285626B6 (sr)
TN (1) TNSN00017A1 (sr)
TR (1) TR200102138T2 (sr)
TW (1) TWI269795B (sr)
UA (1) UA71594C2 (sr)
WO (1) WO2000044744A1 (sr)
ZA (1) ZA200105526B (sr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
SI2510089T1 (sl) 2009-12-08 2015-12-31 Codexis, Inc. Sinteza prazolnih spojin
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
ATE414509T1 (de) 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
UA71594C2 (uk) 2004-12-15
EG23980A (en) 2008-02-27
AU2469400A (en) 2000-08-18
YU53801A (sh) 2004-07-15
BG105841A (en) 2002-04-30
CN1339034A (zh) 2002-03-06
CA2357744A1 (en) 2000-08-03
NO20013665L (no) 2001-07-26
EE200100395A (et) 2002-10-15
DK1149090T3 (da) 2003-06-30
IS2019B (is) 2005-06-15
NZ512804A (en) 2003-07-25
CN1231477C (zh) 2005-12-14
TNSN00017A1 (fr) 2005-11-10
SE9900274D0 (sv) 1999-01-28
ATE236899T1 (de) 2003-04-15
AR022425A1 (es) 2002-09-04
EP1149090A1 (en) 2001-10-31
SK10372001A3 (sk) 2002-02-05
RU2237666C2 (ru) 2004-10-10
CZ300504B6 (cs) 2009-06-03
IS5989A (is) 2001-07-05
CA2357744C (en) 2009-06-16
EE04240B1 (et) 2004-02-16
HUP0105313A2 (hu) 2002-05-29
SI1149090T1 (en) 2003-10-31
SK285626B6 (sk) 2007-05-03
BG65060B1 (bg) 2007-01-31
CZ20012730A3 (cs) 2002-02-13
DE60002042T2 (de) 2003-12-18
NO319719B1 (no) 2005-09-05
WO2000044744A1 (en) 2000-08-03
KR100624054B1 (ko) 2006-09-18
TWI269795B (en) 2007-01-01
JP2002535401A (ja) 2002-10-22
HK1041259A1 (en) 2002-07-05
PT1149090E (pt) 2003-07-31
HU226766B1 (en) 2009-09-28
ZA200105526B (en) 2002-10-04
KR20010101699A (ko) 2001-11-14
IL144107A0 (en) 2002-05-23
DE60002042D1 (de) 2003-05-15
US6511996B1 (en) 2003-01-28
ID30095A (id) 2001-11-01
SA00200895B1 (ar) 2006-11-11
TR200102138T2 (tr) 2001-12-21
HK1041259B (zh) 2003-10-24
DZ3001A1 (fr) 2004-03-27
AU768676B2 (en) 2003-12-18
PL197881B1 (pl) 2008-05-30
ES2193937T3 (es) 2003-11-16
MY119095A (en) 2005-03-31
HUP0105313A3 (en) 2003-01-28
BR0007647A (pt) 2001-10-16
NO20013665D0 (no) 2001-07-26
EP1149090B1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
RS50200B (sr) Kalijumova so (s) - omeprazola
DK1465498T3 (da) Tyggegummi med fyld i midten indeholdende calcium
HRP20000292B1 (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
MXPA04002993A (es) Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios.
AU2001276721A1 (en) Salts of benzimidazole compound and use thereof
AU2003215055A1 (en) Search-on-the fly report generator
CA2260337A1 (en) Therapeutic agents
HRP20030154B1 (en) Preparation of risperidone
MY121394A (en) New crystalline forms
NO20030024D0 (no) Ny <alfa>-krystallinsk form av perindopril tert-butylaminsalt
RS51694B (sr) Nova so perindoprila i farmaceutske kompozicije koje sadrže tu so
GB9514518D0 (en) Guanidine salt inhibitors of NO synthase and cyclooxygenase
ATE283339T1 (de) Reinigungslösung und ihre anwendung
UA83012C2 (ru) Кристаллическая форма натриевой соли 3-пиридил-1-гидроксиэтилиден-1,1-бисфосфоновой кислоты
RS50493B (sr) NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON
AU2003273219A8 (en) Novel compositions and methods for the generation of mhc class ii compounds by peptide exchange
DE69838331D1 (de) Kollagenähnliche verbindungen
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
AU1013101A (en) Formulation of potassium sulfate, sodium carbonate and sodium bicarbonate from potash brine
ATE295154T1 (de) Zusammensetzungen mit langsamer freigabe enthaltend lithium-carbonat
IL152614A0 (en) Derivatives of uridine as antibiotics
AU2003252138A1 (en) Cementitious composition comprising bottom ash, methods of making and use thereof
AU2003264958A1 (en) Double-faced artificial wool cloth
AP9901637A0 (en) Crystalline hydrated sodium salt of (E)-4,6-dichloro-3-(2-oxo-1-phenylpyrrolidin-3-ylidene methyl)-1H-indole-2-carboxylic acid.
IL132344A0 (en) Alkaloid halide salts of swainsonine compositions containing the same and the use thereof